Top Articles - Real Estate

Any good investor will tell you that there are 2 kinds of research you can do on an investment:

Fundamental analysis and technical analysis.

Fundamental analysis gathers a number of facts together about the investment, including history, industry, decision-makers, demographics, market analysis, e

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

tc.

Technical analysis looks at trends of recent purchases of similar investments to try and extrapolate what the future will hold.

Now here’s the deal: Technical analysis is easily automated and therefore incredibly popular among stock market, commodity, forex, and real estate investors. Unfort

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

nately, too many people put too much stock in the results of technical analysis. Frankly, without fundamental analysis, technical analysis falls short.

The best advice I can possibly give you, even if you decide never to invest in international real estate, is to do fundamental analysis. Build a

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

solid foundation of fundamental analysis and you’ll find the technical analysis will be understood easily, quickly, and effectively. Ignore it at your own peril!

So let’s look at each of these types of analyses to determine what you can do to learn about an investment.

Fundamental analysis shou

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

d look at some of the following information:

Who is the property developer?

What is their track record with other properties in the past
Do they turn a profit?
Do their investors walk away happy?
Do people invest with them again and again?
Do they finish projects on ti

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

me, on budget, and within promised parameters?

Will the developer be able to purchase building materials, bring them in, and have the labor to build while maintaining affordability? These are 3 big areas that can increase a price and put a project in jeopardy.

Where is the property

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

What has happened in the area to suggest that it could grow? For example, why are the developers choosing to build there instead of somewhere else in the world?
What are other properties around it selling for? Is this area growing in popularity? How do you know? Will it grow more

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

? When will it reach capacity? What factors would you look to in order to feel that it has reached its capacity.

Has interest been strong on those other investments? Why or why not?

What is the property to be used for?

Is this something that will be supported by other con

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

truction in the area? For example, will a rental location be filled with staff because the area is growing quickly and needs lots of people? Or as another example, will a hotel get booked up because the government is working hard to market the country and prepare beaches and other tourist attract

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ions?

Is the property appropriate for the demographic who it will be marketed to? For example, if the property is a building of condos marketed to seniors, are there senior-appropriate services nearby?

Competition

Who else is building right now? What is their track record

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

You want to see this because if just one never-heard-of-before builder is building, you might not be as attracted to a project as you would be if several big-name builders were all creating projects in the same place.

Who else is investing right now? Is it the Donald Trumps of international

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

real estate investing? There’s a good chance you’ll want to get in on the same deals they do.

What will the “end user” competition be like? Will there be dozens of buyers clamoring for a single unit? That will increase prices and potentially earn you a good return. However, if there is no

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

enough demand, the result would be the opposite.

These are just some of the questions you want to research when doing your fundamental analysis. They are hard questions and require some hard work, which is why a lot of people skip this step altogether.

The second, and more popular, bu

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

t in my opinion, inferior type of analysis is technical analysis. Technical analysis looks at historical pricing and tries to identify patterns which are then forecast for the future.

What makes this method inferior is that pricing information is not always readily available, nor very accurate, on

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

projects like this. After all, if it’s international real estate investing we’re talking about, just what historical pricing do you use? Perhaps you could look at other projects to help you form a baseline but that number will never be completely accurate because:

No two projects are the sam

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

e: to get the best number you need to find an impossible-to-find project: one that is built in the same place by the same developer during the same market conditions in a nearly identical location. Easy task? Not at all!

Even looking at a similar project can skew the numbers because a comple

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ed project is experiencing a different point in the market than a project which could hit the market in a few years… when demand is different.

However, if you manage to find a few projects that are similar, and wish to draw an average price from those in the hopes of creating an approximate b

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

aseline, here is what you’ll need to do:

Chart the project along a timeline with the baseline or average cost of several similar projects. Watch your project for similar movements and if your project makes drastic changes that are different from the other projects, then use that as a warning flag

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

or you.

The most important thing you can have is information and frankly, you can never have enough of it. Every piece of information should inform your opinion and you should act on it by doing the following:

1. Does this piece of information change my opinion of the risk level of the project?

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

2. Does this piece of information change my opinion on the reward level of the project?

3. Do I still feel that the risk/reward ratio is within the acceptable parameters I’m comfortable with?

4. Given my answer to question 3, should I hold the line or should I implement an exit strategy right now

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/140081/toparticles-Do-Your-Homework-and-Stop-Your-Deals-from-Going-Bad.html">Do Your Homework and Stop Your Deals from Going Bad</a>

BB link (for phorums):
[url=http://www.toparticles.org.ua/article/140081/toparticles-Do-Your-Homework-and-Stop-Your-Deals-from-Going-Bad.html]Do Your Homework and Stop Your Deals from Going Bad[/url]

Building a link popularity strategy these days has become very difficult and time consuming. Follow these link popularity basics and you will get good search engine rankings over a long period of time.

UB92s are no longer going to be accepted for facilities billing medical insurance claims by the insurance companies. The UB92 is being replaced by a new form that will allow for reporting the newly required NPI or National Provider Identifier Number.

Tags

Links

Top Articles - Do Your Homework and Stop Your Deals from Going Bad

Related Articles: